115 related articles for article (PubMed ID: 36470118)
1. Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma.
Rej A; Paladhi A; Daripa S; Sarkar D; Bhattacharyya S; Mondal I; Hira SK
Int Immunopharmacol; 2023 Jan; 114():109521. PubMed ID: 36470118
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim.
Park HK; Lee JE; Lim J; Jo DE; Park SA; Suh PG; Kang BH
BMC Cancer; 2014 Jun; 14():431. PubMed ID: 24927938
[TBL] [Abstract][Full Text] [Related]
3. Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma.
Hira SK; Rej A; Paladhi A; Singh R; Saha J; Mondal I; Bhattacharyya S; Manna PP
iScience; 2020 Oct; 23(10):101623. PubMed ID: 33089111
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
5. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
6. Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition.
Rouibah H; Kebsa W; Lahouel M; Zihlif M; Ahram M; Aburmeleih B; Mustafa E; Al-Ameer HJ
Anticancer Agents Med Chem; 2018; 18(3):375-387. PubMed ID: 29318976
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
8. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
Liu X; Yu M; Chen Y; Zhang J
Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
[TBL] [Abstract][Full Text] [Related]
9. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
[TBL] [Abstract][Full Text] [Related]
10. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
Hariharan K; Chu P; Murphy T; Clanton D; Berquist L; Molina A; Ho SN; Vega MI; Bonavida B
Int J Oncol; 2013 Aug; 43(2):670-6. PubMed ID: 23764770
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
14. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
15. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
16. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
[TBL] [Abstract][Full Text] [Related]
18. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
Bodo J; Zhao X; Sharma A; Hill BT; Portell CA; Lannutti BJ; Almasan A; Hsi ED
Br J Haematol; 2013 Oct; 163(1):72-80. PubMed ID: 23889282
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
20. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
Li X; Wei Y; Wei X
Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]